ct-388 - Search News

Roche Agrees to Develop Weight-Loss Therapy With Zealand Pharma

The companies agreed to share profits for the therapy equally in the U.S. and Europe, but Roche will have exclusive rights to commercialization in the rest of the world.

CNBC on MSN · 2d

Roche and Zealand Pharma strike $5.3 billion deal for new obesity drug candidate

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma’s obesity drug candidate.

PharmExec · 1d

Zealand Pharma, Roche Reach Potential $5.3 Billion Deal to Develop Petrelintide for Weight Management

Partnership includes the development of combination products, including a fixed-dose combination of petrelintide and Roche’s dual GLP-1/GIP receptor agonist, CT-388, for weight management.

MarketWatch · 2d

Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche

Zealand Pharma shares rose sharply after the Danish pharmaceutical company struck a licensing and collaboration deal of up to $5.3 billion with Roche. Shares in Zealand were up 25% at 609 Danish kroner in European morning trading Wednesday,

Wall Street Journal · 2d

Novo Nordisk Stock Falls After Roche Strikes Weight-Loss Deal

Swiss pharmaceutical company Roche struck a multibillion-dollar collaboration and licensing deal with Zealand Pharma to co-develop a weight-loss treatment. Shares in Roche rallied in Europe, while Zealand stock surged around 30%.

STAT2d

Lilly CEO got a big payday (and an Olympics treat)

Eli Lilly CEO Dave Ricks made $114 million last year, according to a new proxy statement, a rare instance of a health ...

Zacks.com on MSN2d

RHHBY Enters Into a $5.3B Deal With Zealand Pharma for Obesity Drug

Roche RHHBY announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma for an ...

1don MSN

Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

pharmaphorum10mon

Roche trumpets potential ‘best-in-class’ obesity drug

Roche has reported early clinical data with its candidate obesity therapy CT-388, bought as part of its $3.1 billion takeover of Carmot Therapeutics that was announced last year. A phase 1b trial ...

PMLive2d

Roche and Zealand partner on mid-stage obesity candidate in deal worth $5.3bn

Roche and Zealand Pharma have entered into a partnership worth up to $5.3bn to advance Zealand’s mid-stage obesity candidate petrelintide.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results